Hepatitis C Diagnostic Summit
September 8 – 9, 2016
Centers for Disease Control and Prevention
Tom Harkin Global Communication Center

Division of Viral Hepatitis
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
1600 Clifton Road, NE
Atlanta, GA 30329

Speakers and Moderators

Tanya Applegate, PhD  
Greg Armstrong, MD  
Francisco Averhoff, MD  
Adrian Di Bisceglie, MD  
Bernie Branson, MD  
Michael Chapko, PhD  
George Dawson, PhD  
Claudia Denkinger, MD, PhD  
Brian Edlin, MD  
Jeffrey Engel, MD

Michael Fried, MD  
Lilia Ganova-Raeva, PhD  
Fengxiang Gao, PhD  
Anne Gaynor, PhD  
Camila Graham, MD  
Susan Hariri, PhD  
Scott Holmberg, MD  
Christiane Honisch, PhD  
Daniel Johnson, MD

Saleem Kamili, PhD  
Yury Khudyakov, PhD  
W. Ray Kim, MD  
Julia Kreß, PhD  
Anne Loarec, MD  
Steve Lovell, PhD  
Lesley Miller, MD  
Monica Parker, PhD  
Rick Pesano, MD, PhD

Christos Petropoulos, PhD  
Hong Qi, PhD  
Liisa M. Randall, PhD  
Michael Reed, MD  
Linda Thomas, MS  
Doug Thoroughman, PhD, MS  
John W Ward, MD  
Carolyn Wester, MD, MPH  
Belinda Yen-Lieberman, PhD

Organizing Committee

Saleem Kamili, PhD  
Centers for Disease Control and Prevention

John W Ward, MD  
Centers for Disease Control and Prevention

Anne M Gaynor, PhD  
Association of Public Health Laboratories

Claudia Denkinger, MD, PhD  
Foundation for Innovation New Diagnostics

www.cdc.gov/hepatitis
Thursday, September 8, 2016

8:00 AM - 9:00 AM  Sign-in and on-site registration
9:00 AM - 9:10 AM  Welcome
  Jonathan Mermin, MD, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC
9:10 AM - 9:30 AM  Opening remarks & setting the stage for the summit
  John Ward, MD, Division of Viral Hepatitis, CDC

Session I: Diagnosis and Management of Current HCV Infection – From HCV Testing to Cure
Moderators: Michael Fried, MD and Daniel Johnson, MD
10 min presentations followed by 5 min Q&A

9:30 AM - 9:45 AM  Testing for diagnosis of current HCV infection
  Lesley Miller, MD, Emory University School of Medicine/Grady Hospital
9:45 AM - 10:00 AM  Testing for management and monitoring of anti-viral therapy
  Adrian Di Bisceglie, MD, Saint Louis University School of Medicine, St Louis, MO
10:00 AM - 10:15 AM  Testing for relapse versus re-infection and on-going exposures
  Brian Edlin, MD, Medical officer, NCHHSTP, CDC
10:15 AM - 10:30 AM  Testing of high-risk and special populations
  W. Ray Kim, MD, Stanford University Medical Center, Stanford, CA
10:30 AM - 10:45 AM  HCV national surveillance
  Scott Holmberg, MD, Division of Viral Hepatitis, CDC
10:45 AM - 11:00 AM  Roundtable of speakers with Q&A
11:00 AM - 11:10 AM  Break

Session II: HCV Diagnostics: the Clinical and Public Health Laboratory Setting - Policy, Practice and Data
Moderators: Bernie Branson, MD and Jeffrey Engel, MD
10 min presentation, moderated Q&A at the end of the session

11:10 AM - 11:40 AM  Testing practices and platforms, and challenges in implementing CDC’s updated hepatitis C testing guidelines
  LabCorp- Christos Petropoulos, PhD
  Quest Diagnostics- Rick Pesano, MD, PhD
  Cleveland Clinic- Belinda Yen-Lieberman, PhD

11:40 AM - 11:50 AM  Use of commercial lab data for public health action
  Susan Hariri, PhD, Division of Viral Hepatitis, CDC
11:50 AM - 12:20 PM  Roundtable of speakers with Q&A
12:20 PM - 1:30 PM  Lunch

Session III: Expanding Access to Quality HCV Diagnostics Globally Especially in Resource-limited Settings
Moderators: Claudia Denkinger, MD, PhD and John Ward, MD
10 min presentations followed by 5 min Q&A

1:30 PM - 1:45 PM  Overview of global gaps in diagnostics
  Francisco Averhoff, MD, Division of Viral Hepatitis, CDC
1:45 PM – 2:00 PM  Efforts to improve and make HCV diagnostics affordable globally
  Claudia Denkinger, MD, PhD Tuberculosis and Hepatitis Program, FiND
2:00 PM - 2:15 PM  The pursuit of ‘good enough’ in hepatitis C diagnostics
  Camila Graham, MD, Beth Israel Deaconess Medical Center, Boston, MA
2:15 PM - 2:30 PM  MSF experience with HCV screening, care and monitoring
  Anne Loarec, MD, Médecins Sans Frontières/Doctors without Borders
2:30 PM - 2:45 PM  Break

2:45 PM - 3:00 PM  Development of WHO standards for HCV NATs
  Julia Kreß, PhD, Paul Ehrlich Institute
3:00 PM - 3:15 PM  CDC’s efforts in improving diagnostics: development of proficiency panels
  Saleem Kamili, PhD, Division of Viral Hepatitis, CDC
3:15 PM - 3:30 PM  Roundtable of speakers with Q&A
3:30 PM - 3:45 PM  Closing remarks
  John Ward, MD, Division of Viral Hepatitis, CDC

www.cdc.gov/hepatitis
Friday, September 9, 2016

8:00 AM - 8:15 AM Opening remarks
John Ward, MD, Division of Viral Hepatitis, CDC

Session IV: HCV Diagnostics – New and Improved Technologies
Moderators: Saleem Kamili, PhD and Steve Lovell, PhD
10 min presentations followed by 5 min Q&A

8:20 AM - 8:35 AM Current diagnostic landscape in HCV
Bernie Branson, MD, Scientific Affairs, LLC

8:35 AM - 8:50 AM HCV core antigen Assay
George Dawson, PhD, Abbott

8:50 AM – 9:05 AM Point-of-care HCV antibody assays
Michael Reed, PhD, Orasure

9:05 AM - 9:20 AM Point-of-care HCV core antigen test development
Hong Qi, PhD, Qoo labs

9:20 AM - 9:35AM Point-of-care HCV RNA test
Tanya Applegate, PhD, Kirby Institute, UNSW, AU

9:35 AM - 9:50 AM Break

9:50 AM – 10:05 AM Integrated testing for multiple pathogens - Virome analysis
Christiane Honisch, PhD, Illumina

10:05 AM - 10:25 AM Roundtable of speakers with Q&A

Session V: U.S. Public Health role in HCV Detection, Investigation and Response
Part I – Moderator: Carolyn Wester, MD, MPH
10 min presentations followed by 5 min Q&A

10:30 AM - 10:45 AM Public health laboratory capacity in the United States
Anne Gaynor, PhD, Association of Public Health Laboratories

10:45 AM - 11:00 AM Challenges in using Laboratory Developed Tests in HCV Diagnostics
Monica Parker, PhD, New York State Department of Health

11:00 AM - 11:15 AM Regulatory issues in diagnostic development
Steve Lovell, PhD, U.S. Food and Drug Administration

11:15 AM - 11:30 AM Break

11:30 AM - 11:45 AM Cost-effectiveness of various HCV testing strategies
Michael Chapko, PhD, University of Washington

11:45 AM - 12:00 PM Roundtable of speakers with Q/A

12:00 PM - 1:30 PM Lunch

Part II – Moderator: Greg Armstrong, MD
1:30 PM - 1:45 PM Evolving a state laboratory diagnostic capacity during an HCV outbreak
Fengxiang Gao, PhD, New Hampshire State Department of Health

1:45 PM - 2:00 PM Next Generation Sequencing Technology
Lilia Ganova-Raeva, PhD, Division of Viral Hepatitis, CDC

2:00 PM - 2:15 PM GHOST – outbreak investigations and molecular surveillance
Yury Khudyakov, PhD, Division of Viral Hepatitis, CDC

2:15 PM - 2:30 PM Implementation of GHOST – a Pilot site
Linda Thomas, MS, Tennessee State Department of Health

2:30 PM - 3:00 PM Roundtable of speakers with Q/A

3:00 PM - 3:45 PM Panel Discussion: Key programmatic and policy issues impacting health departments in regards to hepatitis C Carolyn Wester, MD, MPH; Doug Thoroughman, PhD, MS; Liisa M. Randall, PhD

3:45 PM - 4:00 PM Wrap-up and closing remarks
John Ward, MD, Division of Viral Hepatitis, CDC